BACKGROUND: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes. METHODS: In designing the Apathy in DementiaMethylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. CONCLUSION: The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.
RCT Entities:
BACKGROUND: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes. METHODS: In designing the Apathy in DementiaMethylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. CONCLUSION: The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.
Authors: Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Barbara K Martin; Constantine E Frangakis; Paul B Rosenberg; Jacobo E Mintzer; Ira R Katz; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; George Niederehe; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2006-11 Impact factor: 4.105
Authors: E Mulin; E Leone; K Dujardin; M Delliaux; A Leentjens; F Nobili; B Dessi; O Tible; L Agüera-Ortiz; R S Osorio; J Yessavage; D Dachevsky; F R J Verhey; Alfonso J Cruz Jentoft; O Blanc; P M Llorca; P H Robert Journal: Int J Geriatr Psychiatry Date: 2011-02 Impact factor: 3.485
Authors: S Freels; D Cohen; C Eisdorfer; G Paveza; P Gorelick; D J Luchins; R Hirschman; J W Ashford; P Levy; T Semla Journal: J Gerontol Date: 1992-11
Authors: Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer Journal: J Clin Psychiatry Date: 2013-08 Impact factor: 4.384
Authors: Krista L Lanctôt; Sarah A Chau; Nathan Herrmann; Lea T Drye; Paul B Rosenberg; Roberta W Scherer; Sandra E Black; Vijay Vaidya; David L Bachman; Jacobo E Mintzer Journal: Int Psychogeriatr Date: 2013-10-29 Impact factor: 3.878
Authors: Jolien Fleur Leijenaar; Geert Jan Groeneveld; Wiesje Maria van der Flier; Philip Scheltens; Erica Surya Klaassen; Henry Chanoch Weinstein; Geert Jan Biessels; Frederik Barkhof; Niels Daniël Prins Journal: JMIR Res Protoc Date: 2018-03-20
Authors: Roberta W Scherer; Lea Drye; Jacobo Mintzer; Krista Lanctôt; Paul Rosenberg; Nathan Herrmann; Prasad Padala; Olga Brawman-Mintzer; William Burke; Suzanne Craft; Alan J Lerner; Allan Levey; Anton Porsteinsson; Christopher H van Dyck Journal: Trials Date: 2018-01-18 Impact factor: 2.279